The Health Care & Pharmaceutical Committee hosts its Q4 quarterly update, summarizing key antitrust developments and discussing what to expect as the new administration takes office. Experts highlight how regulators are tackling challenges in data-driven markets, with a focus on health care, pharmaceuticals, big tech, and evolving merger reviews. Panelists also share insights from recent cases and offer practical guidance for professionals and students navigating this rapidly evolving landscape.
